About this trial
Intraoperative hypothermia is common in patients having major surgery and the compliance with intraoperative temperature monitoring and management remains poor. Studies suggest that intraoperative hypothermia is an important risk factor of postoperative delirium, which is associated with worse early and long-term outcomes. Furthermore, perioperative hypothermia increases stress responses and provokes immune suppression, which might promote cancer recurrence and metastasis. In a recent trial, targeted temperature management reduced intraoperative hypothermia and emergence delirium. There was also a trend of reduced postoperative delirium, although not statistically significant. This trial is designed to test the hypothesis that intraoperative targeted temperature management may reduce postoperative delirium and improves progression-free survival in older patients recovering from major cancer surgery.
Eligibility criteria
Qualifiers
Age ≥65 years.
Planned potentially curative initial cancer surgery with an expected duration of 2 hours or longer under general anesthesia.
Disqualifiers
Preoperative fever (tympanic temperature ≥38℃).
Known or suspected preoperative infection.
Previous history of schizophrenia, epilepsy, Parkinson disease, myasthenia gravis, or delirium.
Unable to communicate due to severe dementia, language barrier, or coma.
Trial design
Treatments tested in this trial
- Routine thermal management
- Target temperature management
Treatment groups
Sponsors and collaborators
Peking University First Hospital
Lead sponsor
Peking University
Collaborator